27.7 C
New York
Wednesday, June 10, 2026

Tag: incidence

newssourceFORcompanyinformationcontent1marketreleases

Colorado 811 Highlights 811 Day and the Importance of Safe Digging in Colorado

GOLDEN, Colo., Aug. 8, 2025 /PRNewswire/ -- Each year on August 11, 811 Day, Colorado 811 joins with partners and communities across the state...

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...

Boralex annonce le départ de son chef de la direction financière

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce que Bruno Guilmette, Premier vice-président et chef de la direction financière, a choisi de relever de nouveaux défis en saisissant une nouvelle opportunité professionnelle, après près de sept ans passés chez Boralex. Il demeurera en poste jusqu’au 12 septembre 2025 afin d’assurer une transition fluide.

Boralex annonce un résultat d’exploitation du deuxième trimestre comparable à celui de 2024 et poursuit activement ses activités de développement et de construction de...

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce ses résultats pour le deuxième trimestre de l'exercice 2025.

Industries Lassonde inc. annonce ses résultats du deuxième trimestre de 2025

ROUGEMONT, Québec, 07 août 2025 (GLOBE NEWSWIRE) -- Industries Lassonde inc. (TSX : LAS.A) (« Lassonde » ou la « Société ») a annoncé aujourd'hui ses résultats financiers pour le deuxième trimestre de l’exercice 2025.

Saputo annonce ses résultats du premier trimestre de l’exercice 2026 clos le 30 juin 2025

MONTRÉAL, 07 août 2025 (GLOBE NEWSWIRE) -- Saputo inc. (TSX: SAP) (nous, Saputo ou la Société) a divulgué aujourd’hui ses résultats financiers pour le premier trimestre de l’exercice 2026, clos le 30 juin 2025. À moins d’avis contraire, tous les montants inclus dans ce communiqué de presse sont exprimés en millions de dollars canadiens (CAD), sauf les données par action, et sont présentés conformément aux Normes internationales d’information financière (IFRS).

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Trimestre record: Savaria réalise un bénéfice net de 16,3 M $ et atteint une marge du BAIIA ajusté* de 20,6 % au deuxième trimestre...

LAVAL, Québec, 06 août 2025 (GLOBE NEWSWIRE) -- Corporation Savaria («Savaria») (TSX: SIS), un des chefs de file mondiaux de l’industrie de l’accessibilité, est heureuse de présenter les résultats de son 2e trimestre de 2025.

JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio’s DEX-G2 Blood Test For Early Detection of Gastric Cancer

SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance...

Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management

Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector. 
Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector.

- A word from our sponsors -

spot_img
HomeTagsIncidence

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers